Found: 4
Select item for more details and to access through your institution.
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1121973
- By:
- Publication type:
- Article
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01408-6
- By:
- Publication type:
- Article
SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses can originate from cross-reactive CMV-specific T cells.
- Published in:
- eLife, 2023, p. 1, doi. 10.7554/eLife.82050
- By:
- Publication type:
- Article
Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1368290
- By:
- Publication type:
- Article